PLSE icon

Pulse Biosciences

15.42 USD
-0.67
4.16%
Updated Apr 1, 3:10 PM EDT
1 day
-4.16%
5 days
-2.34%
1 month
-13.71%
3 months
-13.32%
6 months
-6.83%
Year to date
-13.32%
1 year
92.99%
5 years
147.51%
10 years
269.78%
 

About: Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Employees: 56

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

86% more call options, than puts

Call options by funds: $1.75M | Put options by funds: $941K

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

5% more capital invested

Capital invested by funds: $98.6M [Q3] → $104M (+$5.16M) [Q4]

0.55% more ownership

Funds ownership: 9.18% [Q3] → 9.73% (+0.55%) [Q4]

0% more funds holding

Funds holding: 72 [Q3] → 72 (+0) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for PLSE.

Financial journalist opinion

Based on 5 articles about PLSE published over the past 30 days

Neutral
Seeking Alpha
4 days ago
Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of the Board of Directors Jon Skinner - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Louella, and I will be your conference operator today.
Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript
Neutral
Business Wire
4 days ago
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the t.
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
Neutral
Business Wire
5 days ago
Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 24th Annual Needham Virtual Health Care Conference. Pulse Biosciences' Management is scheduled to present on Thursday, April 10, 2025, at 9:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentation.
Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
Neutral
Business Wire
3 weeks ago
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by.
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
Neutral
Business Wire
4 weeks ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to 14 new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Equity Incentive Plan. The equity awards were approved and issued on Fe.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 month ago
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming TD Cowen 45th Annual Health Care Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, March 5, 2025, at 10:30 am ET. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of.
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
Neutral
Business Wire
1 month ago
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. “I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled.
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
Neutral
Business Wire
2 months ago
Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its nanosecond PFA Percutaneous Electrode System will be featured in a clinical science session and a video session at the North American Society for Interventional Thyroidology Annual Meeting, being held January 31 through February 1, 2025 in Washington D.C. “To obtain our initial FDA 510(k).
Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
Neutral
Business Wire
2 months ago
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented at the 30th Annual AF Symposium 2025 meeting. The feasibility study is intended to assess the initial safety and efficacy of the Nanosecond PFA 360° Cardiac Catheter System.
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
Neutral
Business Wire
2 months ago
Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA 360° catheter mapped with the Abbott Ensite X 3D Mapping System at the 30th Annual AF Symposium 2025 meeting, being held January 16-18 in Boston, Massachusetts. “Since joining the Company's.
Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
Charts implemented using Lightweight Charts™